108 related articles for article (PubMed ID: 12908547)
1. Ewing tumor biology: perspectives for innovative treatment approaches.
Kovar H
Adv Exp Med Biol; 2003; 532():27-37. PubMed ID: 12908547
[TBL] [Abstract][Full Text] [Related]
2. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.
Miyagawa Y; Okita H; Nakaijima H; Horiuchi Y; Sato B; Taguchi T; Toyoda M; Katagiri YU; Fujimoto J; Hata J; Umezawa A; Kiyokawa N
Mol Cell Biol; 2008 Apr; 28(7):2125-37. PubMed ID: 18212050
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
4. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells.
Li X; Tanaka K; Nakatani F; Matsunobu T; Sakimura R; Hanada M; Okada T; Nakamura T; Iwamoto Y
Int J Cancer; 2005 Sep; 116(3):385-94. PubMed ID: 15818598
[TBL] [Abstract][Full Text] [Related]
5. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors.
Zwerner JP; May WA
Oncogene; 2001 Feb; 20(5):626-33. PubMed ID: 11313995
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
7. Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family.
Amann G; Zoubek A; Salzer-Kuntschik M; Windhager R; Kovar H
Hum Pathol; 1999 Sep; 30(9):1058-64. PubMed ID: 10492040
[TBL] [Abstract][Full Text] [Related]
8. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells.
Thompson AD; Teitell MA; Arvand A; Denny CT
Oncogene; 1999 Sep; 18(40):5506-13. PubMed ID: 10523827
[TBL] [Abstract][Full Text] [Related]
9. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
10. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
[TBL] [Abstract][Full Text] [Related]
11. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
12. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
[TBL] [Abstract][Full Text] [Related]
13. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors.
Hu-Lieskovan S; Zhang J; Wu L; Shimada H; Schofield DE; Triche TJ
Cancer Res; 2005 Jun; 65(11):4633-44. PubMed ID: 15930281
[TBL] [Abstract][Full Text] [Related]
14. EWS/ETS fusions activate telomerase in Ewing's tumors.
Takahashi A; Higashino F; Aoyagi M; Yoshida K; Itoh M; Kyo S; Ohno T; Taira T; Ariga H; Nakajima K; Hatta M; Kobayashi M; Sano H; Kohgo T; Shindoh M
Cancer Res; 2003 Dec; 63(23):8338-44. PubMed ID: 14678994
[TBL] [Abstract][Full Text] [Related]
15. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
16. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
18. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
19. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
